Out of the 153 DLBCL specimens, 87 patient samples (or 56.9%) were categorized as having low MAPK12 expression (Fig. 2a-b), while the remaining 66 samples (or 43.1%) were categorized as having high MAPK12 expression (Fig. 2c-d). This evidence concerns the gene MAPK12 and diffuse large B-cell lymphoma.